Vivos Therapeutics (NASDAQ:VVOS) Issues Earnings Results, Beats Estimates By $0.10 EPS

Posted by Brenda Bartman on Aug 16th, 2026

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.10, Zacks reports. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%.The company had revenue of $5.15 million for the quarter, compared to analysts’ expectations of $5.63 million.

Here are the key takeaways from Vivos Therapeutics’ conference call:

Second-quarter revenue rose 35% to $5.2 million, driven by $1.9 million of additional service revenue from sleep testing and Vivos treatment. Gross profit increased to $3.0 million and gross margin improved to 57%.
Management reported several potential growth initiatives, including remote patient monitoring for an estimated 5,000–7,500 eligible CPAP patients, a planned CPAP DME program that could generate $150,000–$250,000 in monthly contribution margin, expanded EEG/insomnia services, and increased treatment-center capacity.
Vivos said referrals from Sleep Center of Nevada physicians to its treatment centers have increased three- to fourfold since the end of the quarter, with management expecting the resulting production to begin affecting third-quarter results. The company projects cash-flow positivity near the end of 2026 or early 2027 and significant positive EBITDA in fiscal 2027, subject to execution and reimbursement assumptions.
Liquidity remains a major risk: Vivos had only approximately $1.8 million in cash at June 30, used $9.2 million in operating cash during the first half, and stated that its cash is insufficient to fund the next 12 months. The company is not compliant with Nasdaq’s $2.5 million minimum stockholders’ equity requirement and may face delisting proceedings without additional equity financing and cost reductions.
Appliance revenue declined despite higher unit sales because of a shift toward lower-priced preformed products and away from higher-revenue CARE appliances. Meanwhile, proposed cardiology partnerships in Florida and Arizona are expected to require $800,000–$1 million of capital each, with revenue potentially beginning in the first or second quarter of 2027.

Vivos Therapeutics Trading Up 12.4%

Shares of Vivos Therapeutics stock opened at $0.34 on Friday. The firm has a market cap of $4.77 million, a PE ratio of -0.18 and a beta of 6.22. The stock has a 50 day moving average of $0.45 and a 200 day moving average of $0.91. Vivos Therapeutics has a 12 month low of $0.27 and a 12 month high of $5.12.

Analyst Ratings Changes

Several research firms have recently issued reports on VVOS. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. Ascendiant Capital Markets upped their target price on shares of Vivos Therapeutics from $3.00 to $3.10 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vivos Therapeutics has an average rating of “Hold” and an average price target of $2.80.

View Our Latest Stock Analysis on VVOS

Institutional Trading of Vivos Therapeutics

Several hedge funds have recently modified their holdings of VVOS. Connective Capital Management LLC bought a new position in shares of Vivos Therapeutics during the 3rd quarter valued at approximately $620,000. DRW Securities LLC increased its position in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Vivos Therapeutics in the second quarter worth $220,000. Finally, XTX Topco Ltd purchased a new stake in Vivos Therapeutics during the second quarter valued at $65,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.